Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis

Launched by MASSACHUSETTS GENERAL HOSPITAL · Jul 2, 2018

Keywords

ClinConnect Summary

This clinical trial is studying two serious skin conditions called Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). These conditions can cause painful skin rashes and peeling, which can be life-threatening. The researchers want to find out if different treatments can help improve recovery and outcomes for patients who are hospitalized with these conditions. They will compare various treatment options to see which ones work best in stopping the disease from getting worse, speeding up healing, and reducing hospital stays and death rates.

To participate, people must be diagnosed with SJS or TEN by a skin specialist and show specific signs of the disease within a week of starting to feel unwell. Unfortunately, those who are pregnant, under 18, unable to make decisions about their care, in prison, or have had skin peeling for more than a week won’t be able to join the study. While the trial is not yet recruiting participants, those who might be eligible can expect close monitoring and support during their treatment as researchers gather important information to improve care for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • a diagnosis of Stevens Johnsons Syndrome/Toxic Epidermal Necrolysis confirmed by examination of a dermatologist and/or skin biopsy plus described appropriate clinical findings (epidermal necrosis plus two involved mucosal surfaces) presenting within one week of disease onset
• Exclusion Criteria:
• • Pregnancy
• • Age \<18y
• • Decisional impairment
• • Incarceration
• • Onset of skin separation \>7d